Clinical and Biochemical Presentation of Polycystic Ovary Syndrome in Different Age Group

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Ming-I Hsu, Taipei Medical University WanFang Hospital
ClinicalTrials.gov Identifier:
NCT01350895
First received: May 9, 2011
Last updated: November 4, 2013
Last verified: November 2013
  Purpose

To study the clinical and biochemical characteristics women with polycystic ovary syndrome (PCOS) in different aged groups.


Condition
Polycystic Ovary Syndrome

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Clinical and Biochemical Presentation of Polycystic Ovary Syndrome in Different Age Group

Resource links provided by NLM:


Further study details as provided by Taipei Medical University WanFang Hospital:

Enrollment: 781
Study Start Date: February 2011
Study Completion Date: April 2012
Primary Completion Date: April 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts
Experimental Group
Control Group

Detailed Description:

Polycystic ovarian syndrome (PCOS) is the most frequent endocrine disorder of reproductive age women, affecting an estimated 9-18% of all women in this age group. To diagnose of PCOS in early life is especially important because it is now thought to increase metabolic and cardiovascular risks. Investigating PCOS is crucial as it is now considered to increase metabolic and cardiovascular risk, thereby impacting the health of women to a much greater extent than previously thought. We are plan using retrospective analysis to evaluate the clinical and biochemical presentation of PCOS in different aged groups.

  Eligibility

Ages Eligible for Study:   18 Years to 46 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Reproductive age women

Criteria

Inclusion Criteria:

  • Reproductive age women with sufficient data

Exclusion Criteria:

  • Disorders of uterus (e.g. Asherman's Syndrome, Mullerian agenesis) and chromosomal anomalies (e.g. Turner syndrome)
  • women who had had menarche at less than 3 years of age, Day 3 FSH > 15, or who were older than 46
  • women with inadequate clinical/biochemical records
  • and women who had had ovarian cysts or ovarian tumors in ultrasonography examination
  • pregnancy women
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01350895

Locations
Taiwan
Taipei Medical University-WanFang Hospital
Taipei, Taiwan
Sponsors and Collaborators
Taipei Medical University WanFang Hospital
Investigators
Principal Investigator: Ming-I Hsu Taipei Medical University WanFang Hospital
  More Information

No publications provided

Responsible Party: Ming-I Hsu, Attending Doctor, Taipei Medical University WanFang Hospital
ClinicalTrials.gov Identifier: NCT01350895     History of Changes
Other Study ID Numbers: WFH-PCOS-100002
Study First Received: May 9, 2011
Last Updated: November 4, 2013
Health Authority: Taiwan: Department of Health

Keywords provided by Taipei Medical University WanFang Hospital:
Polycystic ovarian syndrome (PCOS)

Additional relevant MeSH terms:
Polycystic Ovary Syndrome
Ovarian Cysts
Cysts
Neoplasms
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Gonadal Disorders
Endocrine System Diseases

ClinicalTrials.gov processed this record on August 21, 2014